The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Mean age-of-onset of familial alzheimer disease caused by presenilin mutations correlates with both increased Aβ42 and decreased Aβ40
Open accessAbstract
The varied ways in which mutations in presenilins (PSEN1 and PSEN2) affect amyloid b precursor protein (APP) processing in causing early-onset familial Alzheimer disease (FAD) are complex and not yet properly understood. Nonetheless, one useful diagnostic marker is an increased ratio of Ab42 to Ab40 (Ab42/Ab40) in patients' brain and biological fluids as well as in transgenic mice and cells. We studied Ab and APP processing for a set of nine clinical PSEN mutations on a novel and highly reproducible enzyme-linked immunosorbent assay (ELISA)-based in vitro method and also sought correlation with brain Ab analyzed by image densitometry and mass spectrometry. All mutations significantly increased Ab42/Ab40 in vitro by significantly decreasing Ab40 with accumulation of APP C-terminal fragments, a sign of decreased PSEN activity. A significant increase in absolute levels of Ab42 was observed for only half of the mutations tested. We also showed that age-of-onset of PSEN1-linked FAD correlated inversely with Ab42/Ab40 (r = -0.89; P = 0.001) and absolute levels of Ab42 (r = -0.83; P = 0.006), but directly with Ab40 levels (r = 0.69; P = 0.035). These changes also partly correlated with brain Ab42 and Ab40 levels. Together, our data suggested that Ab40 might be protective by perhaps sequestering the more toxic Ab42 and facilitating its clearance. Also, the in vitro method we describe here is a valid tool for assaying the pathogenic potential of clinical PSEN mutations in a molecular diagnostic setting.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Scheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., Bird, T. D., Hardy, J., Hutton, M., Kukull, W., et al. (1996) · Nature Medicine · doi:10.1038/nm0896-864 · Cited by 2,599
Wolfe, M. S., Xia, W., Ostaszewski, B. L., Diehl, T. S., Kimberly, W. T., & Selkoe, D. J. (1999) · Nature · doi:10.1038/19077 · Cited by 1,916
Mucke, L., Masliah, E., Yu, G.-Q., Mallory, M., Rockenstein, E. M., Tatsuno, G., Hu, K., Kholodenko, D., Johnson-Wood, K., & McConlogue, L. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-11-04050.2000 · Cited by 1,856
Citron, M., Oltersdorf, T., Haass, C., McConlogue, L., Hung, A. Y., Seubert, P., Vigo-Pelfrey, C., Lieberburg, I., & Selkoe, D. J. (1992) · Nature · doi:10.1038/360672a0 · Cited by 1,757
Borchelt, D. R., Thinakaran, G., Eckman, C. B., Lee, M. K., Davenport, F., Ratovitsky, T., Prada, C.-M., Kim, G., Seekins, S., Yager, D., et al. (1996) · Neuron · doi:10.1016/s0896-6273(00)80230-5 · Cited by 1,478
Self-citationIncreased amyloid-β42(43) in brains of mice expressing mutant presenilin 1
Duff, K., Eckman, C., Zehr, C., Yu, X., Prada, C.-M., Perez-tur, J., Hutton, M., Buee, L., Harigaya, Y., Yager, D., et al. (1996) · Nature · doi:10.1038/383710a0 · Cited by 1,465
Citron, M., Westaway, D., Xia, W., Carlson, G., Diehl, T., Levesque, G., Johnson-wood, K., Lee, M., Seubert, P., Davis, A., et al. (1997) · Nature Medicine · doi:10.1038/nm0197-67 · Cited by 1,271
Saura, C. A., Choi, S.-Y., Beglopoulos, V., Malkani, S., Zhang, D., Rao, B. S. S., Chattarji, S., Kelleher, R. J., Kandel, E. R., Duff, K., et al. (2004) · Neuron · doi:10.1016/s0896-6273(04)00182-5 · Cited by 757 · cited 1×
“…cause loss-of-function became even more important in light of recent evidence that loss of presenilin in mice (Psen) causes neurodegeneration implying that in addition to Ab42-driven gain of aberrant function, loss of PSEN function might also contribute to neurodegeneration [Saura et al., 2004].”
BackgroundThe Pathogenesis of Senile Plaques
DICKSON, D. W. (1997) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199704000-00001 · Cited by 753
Cited by
Karran, E., Mercken, M., & Strooper, B. D. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3505 · Cited by 2,188
Aβ Oligomers – a decade of discovery
Walsh, D. M., & Selkoe, D. J. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04426.x · Cited by 1,938
Masters, C. L., Bateman, R., Blennow, K., Rowe, C. C., Sperling, R. A., & Cummings, J. L. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.56 · Cited by 1,853
The Amyloid State of Proteins in Human Diseases
Eisenberg, D., & Jucker, M. (2012) · Cell · doi:10.1016/j.cell.2012.02.022 · Cited by 1,744
Aβ42‐driven cerebral amyloidosis in transgenic mice reveals early and robust pathology
Radde, R., Bolmont, T., Kaeser, S. A., Coomaraswamy, J., Lindau, D., Stoltze, L., Calhoun, M. E., Jäggi, F., Wolburg, H., Gengler, S., et al. (2006) · The EMBO Reports · doi:10.1038/sj.embor.7400784 · Cited by 986
Oxidative Stress and Neurotoxicity
Sayre, L. M., Perry, G., & Smith, M. A. (2008) · Chemical Research in Toxicology · doi:10.1021/tx700210j · Cited by 867
Intranasal insulin improves cognition and modulates β-amyloid in early AD
Reger, M. A., Watson, G. S., Green, P. S., Wilkinson, C. W., Baker, L. D., Cholerton, B., Fishel, M. A., Plymate, S. R., Breitner, J. C. S., DeGroodt, W., et al. (2008) · Neurology · doi:10.1212/01.wnl.0000265401.62434.36 · Cited by 830
Lanoiselée, H.-M., Nicolas, G., Wallon, D., Rovelet-Lecrux, A., Lacour, M., Rousseau, S., Richard, A.-C., Pasquier, F., Rollin-Sillaire, A., Martinaud, O., et al. (2017) · PLOS Medicine · doi:10.1371/journal.pmed.1002270 · Cited by 616
Wang, C., & Holtzman, D. M. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-019-0478-5 · Cited by 615
“Moreover, mutations in PSEN1 and PSEN2 also result in an increased Aβ42/Aβ40 ratio [111].”
BackgroundWils, H., Kleinberger, G., Janssens, J., Pereson, S., Joris, G., Cuijt, I., Smits, V., Ceuterick-de Groote, C., Van Broeckhoven, C., & Kumar-Singh, S. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0912417107 · Cited by 587
Self-citationThe diagnosis of young-onset dementia
Rossor, M. N., Fox, N. C., Mummery, C. J., Schott, J. M., & Warren, J. D. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70159-9 · Cited by 586
Protein Aggregation in the Brain: The Molecular Basis for Alzheimer’s and Parkinson’s Diseases
Irvine, G. B., El-Agnaf, O. M., Shankar, G. M., & Walsh, D. M. (2008) · Molecular Medicine · doi:10.2119/2007-00100.irvine · Cited by 550
Shen, J., & Kelleher, R. J. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0608332104 · Cited by 485
Nixon, R. A. (2017) · The FASEB Journal · doi:10.1096/fj.201700359 · Cited by 400
The amyloid cascade hypothesis: are we poised for success or failure?
Karran, E., & De Strooper, B. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13632 · Cited by 402
Sun, L., Zhou, R., Yang, G., & Shi, Y. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1618657114 · Cited by 382
Aβ40 Inhibits Amyloid Deposition In Vivo
Kim, J., Onstead, L., Randle, S., Price, R., Smithson, L., Zwizinski, C., Dickson, D. W., Golde, T., & McGowan, E. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.4849-06.2007 · Cited by 415
“Decreases in A 40, without an increase in A 42, have been associated with a subset of AD causing PSEN mutations and the APPV715M mutation (Ancolio et al., 1999; Bentahir et al., 2006; Kumar-Singh et al., 2006).”
BackgroundDe Strooper, B. (2007) · EMBO reports · doi:10.1038/sj.embor.7400897 · Cited by 351
Alzheimer's Aβ42 and Aβ40 peptides form interlaced amyloid fibrils
Gu, L., & Guo, Z. (2013) · Journal of Neurochemistry · doi:10.1111/jnc.12202 · Cited by 327
Buckingham, S. D., Jones, A. K., Brown, L. A., & Sattelle, D. B. (2009) · Pharmacological Reviews · doi:10.1124/pr.108.000562 · Cited by 308
High-fat diet aggravates amyloid-beta and tau pathologies in the 3xTg-AD mouse model
Julien, C., Tremblay, C., Phivilay, A., Berthiaume, L., Émond, V., Julien, P., & Calon, F. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.08.022 · Cited by 288
Genetic insights in Alzheimer's disease
Bettens, K., Sleegers, K., & Van Broeckhoven, C. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70259-4 · Cited by 290
Self-citationPotent amyloidogenicity and pathogenicity of Aβ43
Saito, T., Suemoto, T., Brouwers, N., Sleegers, K., Funamoto, S., Mihira, N., Matsuba, Y., Yamada, K., Nilsson, P., Takano, J., et al. (2011) · Nature Neuroscience · doi:10.1038/nn.2858 · Cited by 280
Self-citationRecent advances in our understanding of neurodegeneration
Jellinger, K. A. (2009) · Journal of Neural Transmission · doi:10.1007/s00702-009-0240-y · Cited by 274
“This was shown in cellular models (Kumar-Singh et al. 2006) and in mouse models when increased levels of Ab-40 in brain while keeping the Ab-42 level decreased plaque burden (Kim et al.”
BackgroundIncreased in Vivo Amyloid-β42 Production, Exchange, and Loss in Presenilin Mutation Carriers
Potter, R., Patterson, B. W., Elbert, D. L., Ovod, V., Kasten, T., Sigurdson, W., Mawuenyega, K., Blazey, T., Goate, A., Chott, R., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005615 · Cited by 236
A β 42 and A β 40: similarities and differences
Qiu, T., Liu, Q., Chen, Y., Zhao, Y., & Li, Y. (2015) · Journal of Peptide Science · doi:10.1002/psc.2789 · Cited by 180
Woodruff, G., Young, J. E., Martinez, F. J., Buen, F., Gore, A., Kinaga, J., Li, Z., Yuan, S. H., Zhang, K., & Goldstein, L. S. B. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.10.018 · Cited by 177
Alzheimer disease pathology as a host response
Castellani, R. J., Lee, H.-G., Zhu, X., Perry, G., & Smith, M. A. (2008) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e318177eaf4 · Cited by 171
Quintero-Monzon, O., Martin, M. M., Fernandez, M. A., Cappello, C. A., Krzysiak, A. J., Osenkowski, P., & Wolfe, M. S. (2011) · Biochemistry · doi:10.1021/bi2007146 · Cited by 118
Shinohara, M., Fujioka, S., Murray, M. E., Wojtas, A., Baker, M., Rovelet-Lecrux, A., Rademakers, R., Das, P., Parisi, J. E., Graff-Radford, N. R., et al. (2014) · Brain · doi:10.1093/brain/awu046 · Cited by 115
“Moreover, increased ratio of production of amyloid-b42 to amyloid-b40 is associated with an earlier age of onset in familial Alzheimer’s disease as a result of presenilin mutations (Duering et al., 2005; Kumar-Singh et al., 2006).”
BackgroundMicroRNAs in Alzheimer’s Disease: Function and Potential Applications as Diagnostic Biomarkers
Wei, W., Wang, Z.-Y., Ma, L.-N., Zhang, T.-T., Cao, Y., & Li, H. (2020) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2020.00160 · Cited by 103
Aβ40 Protects Non-toxic Aβ42 Monomer from Aggregation
Yan, Y., & Wang, C. (2007) · Journal of Molecular Biology · doi:10.1016/j.jmb.2007.04.014 · Cited by 99
Wirths, O., Breyhan, H., Schäfer, S., Roth, C., & Bayer, T. A. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.12.004 · Cited by 97
Aβ40 promotes neuronal cell fate in neural progenitor cells
Chen, Y., & Dong, C. (2009) · Cell Death & Differentiation · doi:10.1038/cdd.2008.94 · Cited by 94
“Ab40 levels are decreased by familial AD mutants, whereas Ab42 levels remain unchanged.(3,4) The beneficial role of Ab40 is also suggested by studies using PS1 knockout models, which undergo neurodegeneration in the absence of Ab production.”
BackgroundLiu, Q., Waltz, S., Woodruff, G., Ouyang, J., Israel, M. A., Herrera, C., Sarsoza, F., Tanzi, R. E., Koo, E. H., Ringman, J. M., et al. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.2482 · Cited by 91
Preclinical validation of a potent γ-secretase modulator for Alzheimer’s disease prevention
Rynearson, K. D., Ponnusamy, M., Prikhodko, O., Xie, Y., Zhang, C., Nguyen, P., Hug, B., Sawa, M., Becker, A., Spencer, B., et al. (2021) · Journal of Experimental Medicine · doi:10.1084/jem.20202560 · Cited by 76
Cacquevel, M., Aeschbach, L., Houacine, J., & Fraering, P. C. (2012) · PLoS ONE · doi:10.1371/journal.pone.0035133 · Cited by 75
Paris, D., Ait-Ghezala, G., Bachmeier, C., Laco, G., Beaulieu-Abdelahad, D., Lin, Y., Jin, C., Crawford, F., & Mullan, M. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.608091 · Cited by 73
Tamboli, I. Y., Prager, K., Thal, D. R., Thelen, K. M., Dewachter, I., Pietrzik, C. U., St. George-Hyslop, P., Sisodia, S. S., De Strooper, B., Heneka, M. T., et al. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.2635-08.2008 · Cited by 68
Stress-induced anhedonia is associated with an increase in Alzheimer’s disease-related markers
Briones, A., Gagno, S., Martisova, E., Dobarro, M., Aisa, B., Solas, M., Tordera, R., & Ramírez, M. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01602.x · Cited by 64
Van Broeck, B., Vanhoutte, G., Pirici, D., Van Dam, D., Wils, H., Cuijt, I., Vennekens, K., Zabielski, M., Michalik, A., Theuns, J., et al. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.10.016 · Cited by 60
Self-citationMolecular mechanism of intramembrane proteolysis by γ-secretase
Tomita, T. (2014) · The Journal of Biochemistry · doi:10.1093/jb/mvu049 · Cited by 58
Sturchio, A., (DIAN), T. D. I. A. C., Dwivedi, A. K., Malm, T., Wood, M. J. A., Cilia, R., Sharma, J. S., Hill, E. J., Schneider, L. S., Graff-Radford, N. R., et al. (2022) · Journal of Alzheimer's Disease · doi:10.3233/jad-220808 · Cited by 57
γ-Secretase and its modulators: Twenty years and beyond
Xia, W. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2019.02.011 · Cited by 54
CD8 signaling in microglia/macrophage M1 polarization in a rat model of cerebral ischemia
Boddaert, J., Bielen, K., ’s Jongers, B., Manocha, E., Yperzeele, L., Cras, P., Pirici, D., & Kumar-Singh, S. (2018) · PLOS ONE · doi:10.1371/journal.pone.0186937 · Cited by 54
Self-citationClinical, biological, and imaging features of monogenic Alzheimer’s disease
Pilotto, A., Padovani, A., & Borroni, B. (2013) · BioMed Research International · doi:10.1155/2013/689591 · Cited by 47
Kaneko, H., Kakita, A., Kasuga, K., Nozaki, H., Ishikawa, A., Miyashita, A., Kuwano, R., Ito, G., Iwatsubo, T., Takahashi, H., et al. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.4244-07.2007 · Cited by 44
Alsaqati, M., Thomas, R. S., & Kidd, E. J. (2018) · The Journals of Gerontology: Series A · doi:10.1093/gerona/glx135 · Cited by 43
“An increase in the Aβ42/Aβ40 ratio is a useful diagnostic marker for early-onset familial AD in the brain, since the age of onset of familial AD was correlated inversely with the Aβ42/Aβ40 ratio and the level of Aβ42 but directly with Aβ40 levels (39).”
BackgroundAre Aβ and Its Derivatives Causative Agents or Innocent Bystanders in AD?
Robakis, N. K. (2010) · Neurodegenerative Diseases · doi:10.1159/000266476 · Cited by 32
A non-human primate model of familial Alzheimer’s disease
Sato, K., Sasaguri, H., Kumita, W., Inoue, T., Kurotaki, Y., Nagata, K., Mihira, N., Sato, K., Sakuma, T., Yamamoto, T., et al. (2020) · doi:10.1101/2020.08.24.264259 · Cited by 29
Dinkel, F., Trujillo-Rodriguez, D., Villegas, A., Streffer, J., Mercken, M., Lopera, F., Glatzel, M., & Sepulveda-Falla, D. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.00220 · Cited by 23
Aβ43 levels determine the onset of pathological amyloid deposition
Tambini, M. D., Yin, T., Yesiltepe, M., Breuillaud, L., Zehntner, S. P., d'Abramo, C., Giliberto, L., & D'Adamio, L. (2023) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.104868 · Cited by 8
Metadata
- Authors
- Kumar-Singh, S., Theuns, J., Van Broeck, B., Pirici, D., Vennekens, K., Corsmit, E., Cruts, M., Dermaut, B., Wang, R., & Van Broeckhoven, C.
- Venue
- Human Mutation
- Publisher
- Hindawi Limited
- Published
- 2006-07
- Volume
- 27
- Issue
- 7
- Pages
- 686-695
- ISSN
- 1059-7794 (ISSN-L)
- 1098-1004
- OpenAlex
- W2010240177
- Cited by
- 323
- References
- 55
- FWCI
- 13.33
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.